Eric van der Helm

Last month, @groendahl and I joined @CARB_X Investor Day in Munich ahead of @ESCMID Global. Always energizing to be among so many teams pushing #AMR innovation forward; from early discovery to clinical-stage programs.

Proud to share our final positive Phase 1 results for SNIPR001 in @LancetMicrobe. Huge thanks to the @sniprbiome team & collaborators. We're using CRISPR to precisely target harmful E. coli bacteria in the gut - helping protect transplant patients from life-threatening infections

Looking forward to speak in Basel

Heading to London for the ⁦@Jefferies⁩ Global Healthcare Conference Nov 17–20. ⁦@sniprbiome⁩ will be on-site, together w. ⁦@groendahl⁩. We’re excited to share insights on our proprietary CRISPR platform and our differentiated #AMR pipeline. #JefferiesHealthcare

I couldn’t be prouder of the SNIPR team today! We’ve just closed a €35 million Series B to push the boundaries of antimicrobial therapy. Huge thanks to our investors, partners, and team members that were part of this journey.

Very proud to see our lead asset now being dosed in patients for the first time. Big congrats to the whole team!

Looking forward to meeting at #BIO2025! Reach out if you'd like to connect with @groendahl and @EricvdHelm in Boston June 16-19. DM here or email partnering@sniprbiome.com

@groendahl and @EricvdHelm will be attending next week's #BioEquity in Bruges🇧🇪. Reach out to learn more about our recent progress and updates of our pipeline. #partnering #BioEquityEurope

I’m looking forward to meeting everyone in Berlin next week, so if you’re also attending @SPRIND feel free to send me a message

SNIPR Biome strengthens IP portfolio with a patent granted for a novel #CRISPR-Cas system! Read more in the press release below.

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases. I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known. People can contact me directly at my first name (as written in my profile) at octant.bio.

On February 25-26, @groendahl and I will be in Basel for the #AMRConference. We’re excited to discuss how @sniprbiome CRISPR technology can help combat #AntimicrobialResistance. If you're attending, feel free to reach out via partnering@sniprbiome.com

Attending #JPM2025 this January? @groendahl and @EricvdHelm will be present and involved in JPM week events. Reach out if you want to meet in San Francisco!

Seven days to #BioEurope! Reach out if you are at #BioEurope and want to know more about @sniprbiome progress in AMR and Microbial Gene Therapy.

Want to know more about building large #phage libraries using cell-free synthesis? Check out our new @sniprbiome scientific article in @OUPSynBio. Big congrats to PhD student Camilla Schoopp Kristensen for leading this work.

Great to see David Baker’s groundbreaking work recognized with the 2024 Nobel Prize in Chemistry. It was an incredible experience to have worked in his lab at the @UWproteindesign over a decade ago and to see the work he's been honored for today!

We are pleased to share that SNIPR Biome has received funding from the @gatesfoundation to advance our microbial gene therapy platform aimed at improving Environmental Enteric Dysfunction in pregnant women from low- and middle-income countries (LMICs). static1.squarespace.com/static/5bacc67…

One of the many perks as an Unveil Bio customer: Edible plasmids! Get your plasmids sequenced at eu1.hubs.ly/H09t7x-0

Exciting news: SNIPR Biome receives funding from @CARB_X to support advancement of CRISPR-medicine SNIPR001 into Phase 1b/2a clinical trials in haematological cancer patients! 👇globenewswire.com/news-release/2…

A study in @NatureComms explores the distribution, evolution and functions of the K1 capsule at a population level and its important role in the pathogenesis of E. coli. go.nature.com/42SBl3Q